Novartis, Amgen partner to jointly develop treatments for Alzheimer's

2 September 2015

Swiss pharma giant Novartis (NOVN: VX) and US biotechnology firm Amgen (Nasdaq: AMGN) have partnered to jointly develop new drugs for Alzheimer's disease. The collaboration is in line with Novartis' strategy to develop a portfolio of treatments for neurological diseases.

Amgen will make upfront as well as subsequent milestone payments to Novartis, if the drug candidate for Alzheimer’s meets certain development targets. No financial terms were disclosed.

Amgen will pay the majority of research-and-development costs for an agreed-upon period following which the two companies will split equally the cost and profits.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK